Literature DB >> 29570830

Familial Blau syndrome without uveitis caused by a novel mutation in the nucleotide-binding oligomerization domain-containing protein 2 gene with good response to infliximab.

Jaime Toral-López1, Luz M González-Huerta2, Mónica Martín-Del Campo3, Olga Messina-Baas4, Sergio A Cuevas-Covarrubias2.   

Abstract

The proband in this study was a 4-year-old Mexican girl with Blau syndrome. She and her affected family members had skin rash and arthritis but no uveitis. Exome sequencing and DNA direct sequencing from blood samples revealed a novel nucleotide-binding oligomerization domain-containing protein 2 gene mutation in the affected family members. This study is the first report of a Mexican family with Blau syndrome showing good infliximab treatment response. The novel mutation in the nucleotide-binding oligomerization domain-containing protein 2 gene (c.1808A>G) enriches the mutation spectrum in Blau syndrome. This family represents one of the few cases of autosomal Blau syndrome with no uveitis; because of phenotype variability, it is important to recognize Blau syndrome's clinical spectrum and recommend genetic consultation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Blau syndrome; CARD15; NOD2; early onset sarcoidosis; infliximab; p.Arg603 mutation

Mesh:

Substances:

Year:  2018        PMID: 29570830     DOI: 10.1111/pde.13475

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  4 in total

Review 1.  Distinguishing Blau Syndrome from Systemic Sarcoidosis.

Authors:  Katherine P Kaufman; Mara L Becker
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-09       Impact factor: 4.806

Review 2.  Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.

Authors:  Tejas P Joshi; Hannah Y Wang; Prazwal Athukuri; Sarah Bohac; Morgan A Farr; Darien Hinson; Justin A Kahla; Nasim Khalfe; Dylan B McBee; Rachel Stroh; Nicole Walters; Vicky Ren
Journal:  Am J Clin Dermatol       Date:  2022-05-23       Impact factor: 6.233

3.  Blau Syndrome and Early-Onset Sarcoidosis: A Six Case Series and Review of the Literature.

Authors:  Ayşenur PaÇ Kisaarslan; Betül SÖzerİ; Nihal Şahİn; Sümeyra Özdemİr ÇİÇek; Zübeyde GÜndÜz; Erkan Demİrkaya; Afig Berdelİ; Serdal Sadet Özcan; Hakan PorazoĞlu; Ruhan DÜŞÜnsel
Journal:  Arch Rheumatol       Date:  2019-11-06       Impact factor: 1.472

4.  Effective treatment of TNFα inhibitors in Chinese patients with Blau syndrome.

Authors:  Jing Chen; Yi Luo; Mengzhu Zhao; Di Wu; Yunjiao Yang; Wen Zhang; Min Shen
Journal:  Arthritis Res Ther       Date:  2019-11-12       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.